Cocrystal Pharma, Inc. — Director's Dealing 2018

May 7, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cocrystal Pharma, Inc. (COCP)
CIK: 0001412486
Period of Report: 2018-05-03

Reporting Person: FROST PHILLIP MD ET AL (Director, 10% Owner)
Reporting Person: Frost Gamma Investments Trust (Trustee)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-05-03	Common Stock	A	105263	$1.90	Acquired	3655265	Indirect

Footnotes

F1: These securities were purchased in the Issuer's public offering.

F2: The amount of securities beneficially owned has been adjusted for the one for 30 reverse stock split effective January 24, 2018.

F3: These securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. Dr. Frost disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that Dr. Frost is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.